FDA lifts clinical hold on Merck KGaA's Stimuvax cancer vaccine study
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Merck KGaA and U.S. affiliate EMD Serono will resume two studies of experimental cancer immunotherapy Stimuvax (BLP liposome vaccine) in patients with non-small cell lung cancer after FDA partially lifted the clinical hold it placed on the entire Stimuvax program in March (1"The Pink Sheet" DAILY, March 23, 2010). A third study, STRIDE, in advanced breast cancer, remains on hold while Merck and the agency decide on next steps, Merck said June 17. The hold followed a case of encephalitis observed in a patient enrolled in an exploratory Phase II trial of the vaccine in patients with multiple myeloma. Protocol in the two NSCLC trials, START and INSPIRE, are being amended to add specific safety measures in response to the serious adverse event
You may also be interested in...
Merck KGaA Cancer Vaccine Studies On Clinical Hold Because Of Encephalitis, But AE Isn't In Lead Indications
The single event occurred in an exploratory study with a very different patient population and regimen than Phase III trials of the vaccine against lung and breast cancers, leaving hope the setback will be short-lived.
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.
MAISI: Navigating The 'Valley Of Death' In Medtech Research Translation
Translating research from proof of concept to clinical investigations is a difficult hurdle to overcome. To succeed, researchers need to design their technology for industrial standard manufacturing early on, Anne Vanhoestenberghe, director for the Manufacture of Active Implants and Surgical Instruments (MAISI), told Medtech Insight.